Longitudinal measurement of HPV copy number in cell-free DNA is associated with patient outcomes in HPV-positive oropharyngeal cancer

Warlow, Sophie J.; Adamowicz, Martyna; Thomson, John P.; Wescott, R; Robert, Christelle; Carey, Lara M.; Thain, Helen; Cuschieri, Kate; Li, Lucy Q; Conn, Brendan; Hay, Ashley; Nixon, Iain J.; Aitman, Timothy J.

doi:10.1016/j.ejso.2022.03.232

Cited by 15 publications

(8 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As we will go onto describe, the mutational landscape of oropharyngeal cancer is complex, and so the determination of a core tumor target set to cover HPV-independent tumors generically has thus far proved elusive. In a study by Warlow et al ( 57 ), the detection of HPV DNA in pretreatment plasma using ddPCR showed high (>90%) agreement with p16 INK4a and the HPV PCR status of the pretreatment (solid) biopsy samples in oropharyngeal cancer patients. The detection of cHPV DNA has also been shown to be indicative of disease recurrence posttreatment.…”

Section: Testing For Hpv In Bloodmentioning

confidence: 92%

Testing for Human Papillomaviruses in Urine, Blood, and Oral Specimens: an Update for the Laboratory

et al. 2023

Self Cite

View full text Add to dashboard Cite

Twelve high-risk alpha human papillomavirus (HPV) genotypes cause approximately 690,000 cancer cases annually, with cervical and oropharyngeal cancer being the two most prominent types. HPV testing is performed in laboratory settings for various applications of a clinical, epidemiological, and research nature using a range of clinical specimens collected by clinicians or by individuals (self-collected specimens).

show abstract

Section: Testing For Hpv In Bloodmentioning

confidence: 92%

Testing for Human Papillomaviruses in Urine, Blood, and Oral Specimens: an Update for the Laboratory

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Early studies using ultrasensitive methods to detect ctHPVDNA have shown great promise for detecting recurrent disease, garnering excitement regarding the potential to overcome the limitations of current surveillance paradigms (Table 1). There is a particularly compelling case for the appropriate development of biomarkers capable of capturing the 30% to 40% of recurrences that are distant metastases, which may otherwise go unnoticed until after an opportunity for meaningful treatment has passed . Several recent studies using the commercial TTMV-HPV DNA assay, which was developed based on work by Chera et al, reported high positive predictive values for recurrence of 95% to 100% .…”

Section: Can We Do Better?mentioning

confidence: 99%

Circulating Tumor HPV DNA for Surveillance of HPV-Positive Oropharyngeal Squamous Cell Carcinoma

Lang Kuhs,

Brenner,

Holsinger

et al. 2023

JAMA Oncol

View full text Add to dashboard Cite

ImportanceHuman papillomavirus (HPV)–positive oropharyngeal squamous cell carcinoma has an overall favorable prognosis, yet a subset of patients will experience devastating disease recurrence. Current surveillance standards for detection of recurrent disease are imperfect. There is growing interest in improving detection of recurrent disease through the use of plasma-based assays able to detect circulating tumor HPV DNA.ObservationsAlthough most circulating tumor HPV DNA assays remain in the research domain, the circulating tumor tissue–modified viral HPV DNA assay became commercially available in the United States in early 2020 and has been increasingly used in the clinical setting. With the rapidly increasing incidence of HPV-positive oropharyngeal squamous cell carcinoma and concomitant expansion of biomarker capabilities for this disease, it is critical to reexamine current posttreatment surveillance practices and to determine whether emerging technologies may be used to improve outcomes for a growing survivor population. However, caution is advised; it is not yet known whether biomarker-based surveillance is truly beneficial, and as is true with any intervention, it has the capacity to cause harm.Conclusions and RelevanceUsing Margaret Pepe’s classic 5 phases of biomarker development for early detection of cancer as a framework, this article reviews the current state of knowledge, highlights existing knowledge gaps, and suggests research that should be prioritized to understand the association between biomarker-based surveillance and patient outcomes. Specific attention is paid to the commercially available tumor tissue–modified viral HPV DNA assay, given its increasing clinical use. This review may serve as a road map for future research and a guide for clinicians considering its adoption in practice. Enrollment of patients into clinical trials incorporating biomarker-based surveillance should be prioritized.

show abstract

“…In longitudinally collected samples post-treatment, cfDNA viral titre has been successfully used as a prognostic marker and early marker of disease progression. Such approaches have shown particular value in EBV-associated nasopharyngeal cancer and human papillomavirus (HPV)-associated oropharyngeal cancers [ 21 – 24 ].…”

Section: Detection Characterisation and Analysis Of Cfdnamentioning

confidence: 99%

Redefining precision radiotherapy through liquid biopsy

McLaren,

Aitman

2023

Br J Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

Longitudinal measurement of HPV copy number in cell-free DNA is associated with patient outcomes in HPV-positive oropharyngeal cancer

Cited by 15 publications

References 32 publications

Testing for Human Papillomaviruses in Urine, Blood, and Oral Specimens: an Update for the Laboratory

Testing for Human Papillomaviruses in Urine, Blood, and Oral Specimens: an Update for the Laboratory

Circulating Tumor HPV DNA for Surveillance of HPV-Positive Oropharyngeal Squamous Cell Carcinoma

Redefining precision radiotherapy through liquid biopsy

Contact Info

Product

Resources

About